Welcome to our dedicated page for In8Bio news (Ticker: INAB), a resource for investors and traders seeking the latest updates and insights on In8Bio stock.
Overview
In8Bio, Inc. is a clinical-stage biopharmaceutical company that specializes in the discovery, development, and commercialization of innovative gamma-delta T cell immunotherapies for cancer treatment. Utilizing state-of-the-art approaches such as allogeneic, autologous, and genetically modified T cells, the company is at the forefront of applying advanced immunology in the fight against both solid and hematologic malignancies. By leveraging its robust DeltEx platform, In8Bio is pioneering the integration of cell-based therapies into standard clinical protocols, a subject of high relevance in the fields of oncology and immunotherapy.
Clinical Programs and Technological Innovation
The company is deeply engaged in multiple clinical programs that advance its gamma-delta T cell product candidates into various stages of clinical investigation. Its innovative approach harnesses the unique ability of gamma-delta T cells to recognize and destroy cancer cells while differentiating between healthy and diseased tissues. The immunotherapies developed by In8Bio are designed to overcome current challenges in cancer treatment by demonstrating resilience in the presence of conventional modalities such as chemotherapy. This novel methodology indicates a significant step forward in addressing persistent gaps in progression-free survival for patients afflicted with difficult-to-treat cancers.
Pipeline and Portfolio
In8Bio maintains a diverse portfolio of cell therapy candidates that target both solid tumors, such as aggressive brain cancers, and liquid tumors, including high-risk hematologic malignancies. The company emphasizes the potential of its genetically modified gamma-delta T cells which are engineered to be chemotherapy-resistant, thereby enabling their effective use in combination with standard-of-care treatments. Its strategic portfolio reflects a deliberate focus on creating therapies that provide robust antitumor activity with a favorable safety profile, which is crucial in clinical settings.
Market Position and Competitive Landscape
Operating within a competitive and dynamic segment of the biotechnology and oncology markets, In8Bio distinguishes itself by being one of the first companies to translate genetically modified gamma-delta T cell therapy into clinical studies. The company’s efforts to integrate advanced cell therapy with conventional cancer management protocols underscore its role as a pioneer in the immunotherapy space. Its scientific and clinical strategies are rooted in extensive research, aiming to expand treatment options for patients with unmet medical needs while setting a benchmark for future research in cell-based therapies.
Research and Development Focus
The core of In8Bio’s business model lies in its commitment to rigorous research and clinical validation. The company employs a systematic approach to clinical investigation, ensuring that its product candidates are evaluated through well-designed studies. This commitment to science and robust clinical trial methodologies not only enhances the credibility of its findings but also contributes to the broader scientific understanding of gamma-delta T cell functions in oncology. The integration of innovative technologies with traditional treatment regimens speaks to the company’s strategy of enhancing therapeutic durability and safety.
Operational Excellence and Strategic Vision
In8Bio is characterized by its deep commitment to scientific excellence and operational transparency. Its research pipeline is supported by meticulous clinical studies that investigate both short-term efficacy and long-term safety profiles of its cell therapies. By positioning its programs at the interface of immunology and oncology, the company provides a pertinent example of how novel biotechnology can offer alternative options for cancer patients. This blend of advanced immunotherapeutic strategies and rigorous clinical science reinforces In8Bio’s reputation as a credible and knowledgeable entity in the biopharmaceutical landscape.
Investor Insights and Frequently Asked Questions
Investors and industry researchers looking into In8Bio will find that the company’s emphasis on gamma-delta T cell therapies offers a unique intersection of cellular immunotherapy and targeted cancer treatments. The detailed clinical programs, alongside strategic R&D initiatives, provide ample context on the company’s approach to addressing unmet needs in oncology. By maintaining a balanced perspective on both the promise and challenges inherent in advanced cell therapies, In8Bio continues to contribute to the evolution of cancer treatment paradigms with ongoing scientific rigor and clinical evaluation.
IN8bio (Nasdaq: INAB) announced a poster presentation at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on November 13, 2021. Dr. Kate Rochlin will present preclinical data on the potential of DeltEx drug-resistant immunotherapy gamma-delta T cells combined with PARP inhibitors to enhance tumor immunogenicity. Notably, temozolomide and niraparib resulted in up to a 29-fold increase in NKG2DL expression in resistant glioblastoma cell lines. This indicates the potential of orthogonal therapies to improve clinical efficacy against solid tumors.
IN8bio, Inc. (Nasdaq: INAB) raised $32.3 million in net proceeds from its IPO, enhancing its capital for clinical programs. The company completed patient dosing of INB-100 in a Phase 1 trial for leukemia while also publishing preclinical data on INB-200 in Scientific Reports. Financial results for Q3 2021 show a cash position of $40.7 million, with R&D expenses rising to $1.4 million. Net loss for the quarter was $3.4 million, compared to $1.7 million in Q3 2020. IN8bio continues to expect initial trial results in 2022 and topline results for all cohorts in 2023.
IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company, announced its participation in three scientific conferences this November. Presentations will cover gammas-delta T-cell therapies aimed at treating various cancers. Key events include the Protein & Antibody Engineering Summit on November 4, the SITC Annual Meeting on November 13, and the Society for Neuro-Oncology meeting on November 19. Presenters include top executives and scientists from IN8bio, showcasing innovative cancer treatment approaches using the DeltEx platform.
IN8bio announced significant survival benefits from concurrent dosing of MGMT-modified gamma-delta T cells with Temozolomide (TMZ) in high-grade glioma models. The findings, published in Scientific Reports, support the clinical development of the company’s Drug Resistant Immunotherapy (DRI) technology. Currently, a Phase 1 trial is evaluating DRI with TMZ in glioblastoma multiforme at the University of Alabama at Birmingham. This approach aims to enhance tumor response while maintaining immune functionality.
IN8bio, a clinical-stage biopharmaceutical company, announced that CEO William Ho will present at BioFuture 2021 on October 5 at 10:30 a.m. EDT and participate in a panel on oncology at 1:30 p.m. EDT. Additionally, Kate Rochlin, VP of Operations, will present on gamma-delta T-cell programs at the Advanced Therapies Congress & Expo 2021 the same day at 11:30 a.m. EDT. IN8bio focuses on innovative therapies for tumors using its DeltEx platform, with two Phase 1 trials ongoing for gamma-delta T-cell products targeting glioblastoma and leukemia.
IN8bio, Inc. announced operational and financial highlights for Q2 2021, reporting significant progress in its Phase 1 clinical trials for INB-200 and INB-100. The successful completion of the first cohort treatment in both trials demonstrates strong potential in solid tumors and leukemia. Following a $40M IPO in August 2021, the company bolstered its cash position to $32.6M. However, IN8bio recorded a net loss of $3.1M for the quarter, with R&D expenses rising to $2.1M, indicating ongoing investment in its clinical programs.
IN8bio, a clinical-stage biopharmaceutical company, announced that CEO William Ho will present at two virtual events: NewYorkBIO Virtual Breakfast Series on August 31 at 9 am EDT, and H.C. Wainwright’s 23rd Annual Global Investment Conference from September 13-14. The presentations will highlight the company's innovative gamma-delta T-cell therapies using its DeltEx platform. The H.C. Wainwright presentation will be available for 90 days post-release. IN8bio is currently conducting Phase 1 clinical trials for its lead product candidates targeting glioblastoma and leukemia.
IN8bio has completed dosing for the first cohort in a Phase 1 clinical trial of INB-100, a gamma-delta T-cell therapy for leukemia patients undergoing haploidentical stem cell transplant. No severe adverse infusion reactions or dose limiting toxicities were reported among the three patients. The first two patients remain in complete remission over one year post-dosing. The trial aims to evaluate safety, tolerability, and overall survival, with topline data expected in 2023. IN8bio focuses on innovative T-cell therapies to improve treatment outcomes for leukemia and other cancers.
IN8bio (Nasdaq: INAB) has appointed Emily Fairbairn and Luba Greenwood to its Board of Directors. Both appointees bring extensive experience in the biopharmaceutical and life sciences sectors. Fairbairn, an influential investor and former CEO of Ascend Capital, focuses on corporate governance, while Greenwood's background includes leadership roles at Google Life Sciences and Roche. Their terms will end at the 2022 annual stockholders' meeting. IN8bio aims to advance its clinical-stage gamma-delta T-cell therapies for cancer treatment, utilizing its innovative DeltEx platform.
IN8bio, Inc. (Nasdaq: INAB) has announced the pricing of its initial public offering (IPO) at $10 per share, totaling gross proceeds of $40 million before expenses. The offering consists of 4,000,000 shares and is expected to close on August 3, 2021. Additionally, an underwriter option allows for 600,000 more shares to be purchased. IN8bio specializes in gamma-delta T cell therapies for cancer treatment and is currently conducting Phase 1 trials for its lead candidates targeting glioblastoma and leukemia.
FAQ
What is the current stock price of In8Bio (INAB)?
What is the market cap of In8Bio (INAB)?
What is the primary focus of In8Bio, Inc.?
How does In8Bio approach cancer treatment differently?
Which types of cancers does In8Bio target?
What makes the company’s technology innovative?
How does In8Bio ensure the safety of its therapies?
In what stage of development is In8Bio’s therapy pipeline?
How does In8Bio differentiate itself from other biopharmaceutical companies?
What benefits do gamma-delta T cells offer in cancer treatment?
